Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

ZURICH (Reuters) - Switzerland’s Relief Therapeutics and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19.

Aviptadil | C147H237N43O43S - PubChem

Relief and NeuroRx said the pact with Switzerland’s Bachem, to supply peptides, and U.S. generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat 1 million patients, should the drug prove effective in the studies.

SEPTEMBER 30, 2020

https://www.reuters.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company